Mackenzie Financial
PRVB

Mackenzie Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Mackenzie Financial’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-57,141
Closed -$604K – 1638
2022
Q4 		$604K Buy
+57,141
New +$461K ﹤0.01% 869

Other funds holding PRVB

Sessa Capital
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Mackenzie Financial's PRVB Position: Q1 2023 in Review

Mackenzie Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 57,141 shares — an estimated $604K sold.

Mackenzie Financial first reported a position in PRVB in Q4 2022 and held it in 1 quarter. The position peaked at $604K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Mackenzie Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 57,141 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $604K.
  • Mackenzie Financial first reported a position in Provention Bio, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Mackenzie Financial's Provention Bio, Inc. Common Stock position peaked at $604K in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.